IDEAYA Biosciences

IDEAYA Biosciences is an oncology-focused precision medicine company that discovers and develops targeted therapeutics using synthetic lethality. The company designs small-molecule inhibitors for molecularly defined cancer populations, progressing clinical candidates such as darovasertib for uveal melanoma alongside MAT2A and PARG inhibitors for genetically selected tumors. Through biomarker identification and companion diagnostic strategies, IDEAYA Biosciences delivers targeted therapies tailored to tumor genetics.